ArticleThe Journal of biological chemistry2026
Protein M of NADC30-like PRRSV induces MARCH6-mediated K33-linked polyubiquitination of SLA-DRA.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NADC30-like porcine reproductive and respiratory syndrome virus (PRRSV) has replaced the high-pathogenicity PRRSV (HP-PRRSV) as the predominant circulating strain in China. Unlike HP-PRRSV, NADC30-like PRRSV exhibits increased genetic diversity and enhanced persistence for persistent infection, along with altered host immune responses, which collectively complicate disease control. In this study, we found that infection with the NADC30-like representative strain XM2020 induced a weaker antibody response than infection with the HP-PRRSV strain HuB2, and that SLA-DRA expression was downregulated. In vitro analyses further demonstrated that this suppression of SLA-DR in peripheral blood mononuclear cells is independently of viral replication. Mechanistically, XM2020-M binds to SLA-DRA and recruits the E3 ubiquitin ligase MARCH6, promoting K33-linked polyubiquitination and proteasomal degradation of SLA-DRA, a function not observed for HuB2-M. In addition, XM2020-M stabilizes MARCH6 by inhibiting its degradation, thereby enhancing its ubiquitin ligase activity. Further mapping identified residue 93 of XM2020-M as a critical determinant of this process. Collectively, these findings reveal a novel immune evasion mechanism by which XM2020-M impairs antigen presentation by targeting the degradation of SLA-DRA, which may contribute to altered adaptive immune responses and viral persistence associated with NADC30-like strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.